Oxycodone Immunoassay Conjugates for Signal Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current homogeneous immunoassays face challenges in detecting oxycodone and its metabolites due to difficulties in providing antibodies that modulate the activity of labels bound to them, limiting the effectiveness of these assays in monitoring and treating patients.
Innovation Solution
Development of immunogenic conjugates, such as glucose-6-phosphate dehydrogenase (G6PDH) conjugates, for preparing antibodies that can modulate the signal in immunoassays for oxycodone and its metabolites, allowing for accurate detection in samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If homogeneous immunoassays are used for detecting oxycodone and its metabolites, then the advantage of not requiring separation steps is achieved, but the difficulty of providing antibodies that will modulate the activity of a label bound to the antibodies or an analog of the analyte limits the effectiveness
Solution Approach 1:
The patent introduces a hapten-carrier conjugate as an intermediary component in the homogeneous immunoassay system. The hapten (oxycodone analog) is conjugated to a carrier protein to create an immunogen that elicits antibody production. This intermediary structure enables the antibody to recognize and bind to the analyte while allowing label modulation, resolving the contradiction between assay simplicity and effectiveness.
Solution Approach 2:
The patent modifies the chemical structure of oxycodone by creating hapten derivatives with specific modifications (e.g., hydroxyl group modifications, carbamate linkages). These parameter changes in the molecular structure enable the development of antibodies with appropriate binding characteristics that can modulate label activity in homogeneous assay conditions, thereby improving assay effectiveness while maintaining simplicity.
2Measurement precision
If antibodies are developed to bind to oxycodone analogs, then the ability to detect the analyte is improved, but the difficulty of providing antibodies that modulate label activity limits the assay performance
Solution Approach 1:
The patent segments the antibody development process into distinct components: hapten synthesis, carrier conjugation, immunization protocol, and antibody selection. By dividing the complex task of developing label-modulating antibodies into manageable segments, the patent achieves both detection precision and manageable development complexity.
Solution Approach 2:
The patent creates hapten copies of oxycodone with modified structures that serve as surrogate targets for antibody development. These copied structures allow researchers to develop antibodies against well-defined targets that are easier to characterize and optimize for label modulation, thereby improving detection accuracy while reducing development complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective detection and quantification of oxycodone and its metabolites in samples, enhancing the monitoring and treatment of patients by providing a reliable and accurate method for these narcotics.
Implementation Method 1
Antibodies bind to label conjugates in accordance with the principles described thereby providing requisite modulation of signal from the label of the conjugates by the binding of antibodies to the conjugate
Data Source
AI summary
Compositions, methods, and kits are disclosed directed at haptens, immunogens and immunoassays for oxycodone and metabolites thereof. The compounds are exemplified by compounds of the Formula I. The method comprises providing in combination in a medium (i) a sample suspected of containing oxycodone and/or oxycodone metabolites, a compound of the Formula I wherein R4 or R5 is a label, and an antibody for oxycodone or a metabolite thereof. The medium is examined for the presence of a complex comprising the labeled compound of Formula I where the presence of such as complex indicates the presence of oxycodone or oxycodone metabolite in the sample.